Horizon Therapeutics and Roche rank among the top pharma companies in terms of reputation among rare disease patient groups, according to a recent report compiled by U.K. consultancy PatientView.
Published Tuesday, the 2022 Corporate Reputation of Pharma survey asked 426 rare disease patient groups representing some 3.3 million patients to assess the performance of 34 drugmakers in the space.
The report noted that pharma has steadily improved its reputation among rare disease patient groups over the past five years. Most respondents praised drugmakers’ abilities to provide products that are beneficial to patients and innovating on breakthrough treatments.
Still, the industry scored lower in 2022 for key activities that are meaningful to these patient populations, including fair pricing policies and access to medicines.
Out of the 34 companies, Horizon was ranked first among rare disease patient groups familiar with the brand, followed by Roche and Takeda Pharmaceuticals. Out of 31 companies, Roche was assessed as the top company by rare disease patient groups working with the company.
Narrowing the field to the 15 Big Pharma companies, Roche was ranked first among patient groups familiar with the brand and those working with the company. Takeda took silver in both of the latter surveys.
PatientView noted in its announcement that separate analyses were conducted to focus on patient groups dealing with bleeding disorders and Roche was assessed as the top pharma company patient groups were familiar with and worked with.
“The respondent rare-disease patient groups feel that the sharing of their evaluation and experiences on whether the pharma industry (and individual pharma companies) meets patient needs and expectations will help the industry gain valuable insights into improvement,” PatientView stated in a press release.
In addition to the top performers according to the rare disease patient groups, UCB experienced the greatest jump in reputational strength among groups familiar with the brand, leaping five spots from 2021 to 2022. AstraZeneca and Octapharma both rose four spots in the rankings, too.
Meanwhile, among companies that patients were working with, CSL Behring jumped six spots, while Boehringer Ingelheim rose three spots.
This is the latest pharma corporate reputation survey released by PatientView, which unveiled its overall industry assessment in May.
In that survey, Roche, ViiV Healthcare and Horizon topped the list while Pfizer slipped from the highest tier. Patient groups indicated that the bond forged between pharma and consumers during the three-year COVID-19 pandemic remained as strong as ever.
